Eloralintide_Dosage, benefits & legal status
Also known as LY3841136
An experimental weekly fullness-hormone shot for weight loss.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Eloralintide?
Plain language first. The technical label stays, but it never stands alone.Overview
It copies the pancreas's fullness hormone for weight loss, designed to be easy to tolerate. It is still in trials.
Eloralintide is an amylin receptor agonist from Eli Lilly.
What it's used for
An experimental weekly shot that copies a natural fullness hormone for weight loss, positioned as easy to tolerate.
How does Eloralintide work?
What it does in the body, and where.Eloralintide is an amylin receptor agonist designed with tolerability as the main goal.
- 01It signals fullness through amylin receptorsA separate route from the GLP-1 drugs.
- 02Built to be easier to tolerateThe gut side effects that make people stop taking GLP-1 drugs are the problem this is trying to design around.
- 03InvestigationalPhase 2 published in 2025. Not approved.
Acts on one receptor.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Weight loss, designed to be easier on the stomach than the GLP-1 drugsInvestigational
The published record
30
Records indexed for Eloralintide
27 in humans, 3 of them original studies.
22 registered trials, 1 with posted results.
Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 12 September 2026.

At a glance
Four things to know about Eloralintide
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
10 mg
Half-life
14 to 16 days
How much, and do you cycle it?
The range, and whether you take breaks.1 up to 9 mg per week (trial doses), weekly. Not cycled in the trialsTrial dose
Given continuously for the whole study period: 48 weeks in phase 2, 75 to 80 weeks in phase 3. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.
How long does it stay in the body?
The half-life, and where the figure comes from.14 to 16 daysTrial protocol
Source: Briere, et al. Mol Metab 2025, PMID 41109426. ADA 2025 abstract 882-P
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
Your draw
20 / 100 unitsEloralintide starts at $79.00 across 4 vendors, typically $13.00 per mg.
4 listings, last read Sep 5, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized Eloralintide keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- No formal contraindications established
- Pregnancy
Stop and get help
- Vomiting badly enough that you cannot keep fluids down
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Notably easier on the stomach than the GLP-1 drugs
- Reduced appetite in about a fifth of people, headache in about one in eight
- Nausea in about a third at higher doses, against 14% on placebo
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Eloralintide approved?
And where the numbers on this page come from.No. Eloralintide is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- CheckedSeptember 2026
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
- Reviewed8 September 2026
What else is like Eloralintide?
Others in Amylin analogs, side by side.If you're weighing Eloralintide, it's worth reading Cagrilintide, Amycretin, and Pramlintide in the same class.
An experimental weekly fullness-hormone shot for weight loss.
- Dose
- 1 up to 9 mg per week (trial doses)
- How often
- Weekly
A weekly fullness-hormone shot, often paired with semaglutide for bigger loss.
- Dose
- 0.3 up to 4.5 mg per dose (start low, increase slowly)
- How often
- Weekly
An experimental two-in-one weight-loss compound, as a pill or a shot.
- Dose
- 0.3 up to 60 mg per week (start low, increase slowly)
- How often
- Weekly/daily
An approved mealtime shot used with insulin to blunt blood-sugar spikes and hunger.
- Dose
- 0.015 up to 0.12 mg per dose (start low, increase slowly)
- How often
- With meals
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Eli Lilly, phase 2 results for eloralintide in adults with obesity or overweight, presented at ObesityWeek and published in The Lancet(2025)263 adults, 48 weeks. Mean weight reduction by dose on the efficacy estimand: 9.5 percent at 1 mg, 12.4 percent at 3 mg, 17.6 percent at 6 mg, 20.1 percent at 9 mg, against 0.4 percent on placebo. Lilly notes the endpoints were not adjusted for multiplicity.
Last reviewed 8 September 2026
Beyond these, 30 records are indexed. Browse the records
